Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts - Bortolomeazzi, Michele; Keddar, Mohamed Reda; Montorsi, Lucia; Acha-Sagredo, Amelia; Benedetti, Lorena; Temelkovski, Damjan; Choi, Subin; Petrov, Nedyalko; Todd, Katrina; Wai, Patty; Kohl, Johannes; Denner, Tamara; et al. (Gastroenterology (New York, N.Y. 1943), 2021)
Keywords: Anti-PD1 Immunotherapy; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Biomarkers, Tumor - genetics; CD8 T cells; CD8-Positive T-Lymphocytes - drug effects; CD8-Positive T-Lymphocytes - immunology; Clinical Trials as Topic; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - genetics; Colorectal Neoplasms - immunology; Cytotoxicity, Immunologic - drug effects; Exome Sequencing; Gene Expression Profiling; Humans; Immune Checkpoint Inhibitors - adverse effects; Immune Checkpoint Inhibitors - therapeutic use; Immunogenetic Phenomena; Immunogenetics; Interferon Gamma; Lymphocytes, Tumor-Infiltrating - drug effects; Lymphocytes, Tumor-Infiltrating - immunology; Mutation; Nivolumab - adverse effects; Nivolumab - therapeutic use; Original Research; Predictive Value of Tests; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Reproducibility of Results; RNA-Seq; Time Factors; Transcriptome; Treatment Outcome; Tumor Microenvironment; Tumor Mutational Burden; Tumor-Associated Macrophages - drug effects; Tumor-Associated Macrophages - immunology; Wnt Signaling; Wnt Signaling; A-FRET; CD; DB-CRC; T-cell; WES; TMB; mIF; TME; GzB; TCGA; Anti-PD1 Immunotherapy; RNA-seq; CRC; SNV; Tumor Mutational Burden; PD1; PDL1; Interferon Gamma; B2M; nDB-CRC; IMC; CD8 T cells